[go: up one dir, main page]

RU2434638C2 - Вакцина альфа токсоида с.perfringens - Google Patents

Вакцина альфа токсоида с.perfringens Download PDF

Info

Publication number
RU2434638C2
RU2434638C2 RU2007142337/10A RU2007142337A RU2434638C2 RU 2434638 C2 RU2434638 C2 RU 2434638C2 RU 2007142337/10 A RU2007142337/10 A RU 2007142337/10A RU 2007142337 A RU2007142337 A RU 2007142337A RU 2434638 C2 RU2434638 C2 RU 2434638C2
Authority
RU
Russia
Prior art keywords
vaccine
perfringens
antigen
vaccine according
toxoid
Prior art date
Application number
RU2007142337/10A
Other languages
English (en)
Other versions
RU2007142337A (ru
Inventor
Хучаппа ДЖАЯППА (US)
Хучаппа ДЖАЯППА
Кевин О`КОННЕЛЛ (US)
Кевин О`КОННЕЛЛ
Original Assignee
Шеринг-Плоу Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36820082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2434638(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг-Плоу Лтд. filed Critical Шеринг-Плоу Лтд.
Publication of RU2007142337A publication Critical patent/RU2007142337A/ru
Application granted granted Critical
Publication of RU2434638C2 publication Critical patent/RU2434638C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к области медицины и касается вакцин, которые содержат альфа токсоиды C.perfringens. Представленная вакцина содержит супернатант альфа токсоида C.perfringens, за исключением C.perfringens типа С, который был сконцентрирован путем ультрафильтрации и имеет две или более единицы Общей Комбинирующей Силы (TCP). Такая вакцина может быть использована для защиты животных против клостридиальных заболеваний, вызванных C.perfringens, за исключением C.perfringens типа С. 10 з.п. ф-лы, 23 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061

Claims (11)

1. Вакцина для защиты животных против клостридиальных заболеваний, вызванных C.perfringens за исключением C.perfringens типа С, содержащая супернатант альфа токсоида C.perfringens, за исключением C.perfringens типа С, который был сконцентрирован путем ультрафильтрации и имеет две или более единицы Общей Комбинирующей Силы (TCP), в которой указанный супернатант альфа токсоида C.perfringens содержит альфа токсоид антиген, при условии, что вакцина содержит альфа токсоид антиген только одного типа C.perfringens.
2. Вакцина по п.1, в которой антиген находится в бесклеточном препарате.
3. Вакцина по п.1, которая предназначена для введения курам.
4. Вакцина по п.1, где от одной до двух доз вакцины в количестве 0,25-0,6 мл вакцины на дозу достаточно для индуцирования по меньшей мере четырех антитоксиновых единиц (A.U.) анти-альфа токсин антител на мл антисыворотки кур, вакцинированных вакциной.
5. Вакцина по п.1, в которой упомянутый антиген представляет собой альфа токсоид C.perfringens Тип А.
6. Вакцина по п.1, которая дополнительно содержит адъювант.
7. Вакцина по п.1, которая содержит антиген в водно-масляной эмульсии.
8. Вакцина по п.7, в которой водно-масляную эмульсию готовят из 70% масляной фазы и 30% водной фазы.
9. Вакцина по п.1, которая предназначена для введения курам и содержит антиген в водно-масляной эмульсии, причем от одной до двух доз вакцины в количестве 0,25-0,6 мл вакцины на дозу достаточно для индуцирования по меньшей мере четырех антитоксиновых единиц (A.U.) анти-альфа токсин антител на мл антисыворотки кур, вакцинированных вакциной.
10. Вакцина по п.1, которая дополнительно содержит C.perfringens бета токсоид.
11. Вакцина по п.10, которая дополнительно содержит один или более бактериальных антигенов из E.coli.
RU2007142337/10A 2005-04-18 2006-04-17 Вакцина альфа токсоида с.perfringens RU2434638C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67228905P 2005-04-18 2005-04-18
US60/672,289 2005-04-18

Publications (2)

Publication Number Publication Date
RU2007142337A RU2007142337A (ru) 2009-05-27
RU2434638C2 true RU2434638C2 (ru) 2011-11-27

Family

ID=36820082

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007142337/10A RU2434638C2 (ru) 2005-04-18 2006-04-17 Вакцина альфа токсоида с.perfringens

Country Status (25)

Country Link
US (2) US8980283B2 (ru)
EP (1) EP1874344B1 (ru)
JP (2) JP5243951B2 (ru)
KR (1) KR20080005277A (ru)
CN (1) CN101198352B (ru)
AR (1) AR054251A1 (ru)
AU (1) AU2006236365B2 (ru)
BR (1) BRPI0610843B1 (ru)
CA (1) CA2606180C (ru)
CR (1) CR9443A (ru)
DK (1) DK1874344T3 (ru)
ES (1) ES2583484T3 (ru)
IL (1) IL186701A0 (ru)
MA (1) MA29406B1 (ru)
MX (1) MX2007013053A (ru)
MY (1) MY149604A (ru)
NZ (1) NZ562637A (ru)
PE (1) PE20061398A1 (ru)
RU (1) RU2434638C2 (ru)
SG (1) SG186672A1 (ru)
TN (1) TNSN07387A1 (ru)
TW (1) TWI311057B (ru)
UA (1) UA98099C2 (ru)
WO (1) WO2006113772A1 (ru)
ZA (1) ZA200709516B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
BRPI0710023A2 (pt) * 2006-03-30 2011-08-02 Embrex Inc métodos e composições para a vacinação de aves domésticas
KR20080110908A (ko) * 2006-04-17 2008-12-19 쉐링-프라우 리미티드 재조합의 약독화된 클로스트리듐 유기체 및 백신
WO2008055069A2 (en) * 2006-10-27 2008-05-08 Dow Agrosciences Llc Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
US20100062025A1 (en) * 2006-11-20 2010-03-11 Intervet International B.V. Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine
US7820171B2 (en) * 2007-04-12 2010-10-26 Pradip Maiti Use of avian anti-methanogen antibodies for reduction of methane production
CA2685533C (en) 2007-06-22 2019-07-02 University Of Guelph Vaccine against clostridium perfringens
US8956628B2 (en) * 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
US8277651B2 (en) 2009-03-13 2012-10-02 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN102008720B (zh) * 2010-07-20 2015-02-25 东北农业大学 抗魏氏梭菌病转基因植物疫苗及其制作方法
EP2793934B1 (en) * 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
CN102657683B (zh) * 2012-06-02 2014-05-07 哈尔滨工业大学 一种免疫类毒素的制备方法
CN102698259B (zh) * 2012-06-12 2017-02-08 北京中海生物科技有限公司 一种鸡坏死性肠炎（a型）灭活疫苗制备方法
CN102688484B (zh) * 2012-06-13 2016-03-30 北京中海生物科技有限公司 一种鸡坏死性肠炎（c型）灭活疫苗的生产方法
CN104736171B (zh) 2012-10-26 2018-11-06 英特维特国际股份有限公司 交叉保护的沙门氏菌疫苗
CN103463632B (zh) * 2013-09-05 2016-01-06 山东农业大学 牛羊肠毒血症的d型产气荚膜梭菌类毒素疫苗的制备方法
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
CN103861094A (zh) * 2014-03-27 2014-06-18 山东农业大学 一种产气荚膜梭菌α毒素基因工程疫苗及其应用
CN104131022A (zh) * 2014-08-01 2014-11-05 中国农业科学院兰州兽医研究所 产气荚膜梭菌α、β1、β2、ε毒素共表达载体及其构建方法和表达方法
CN104531730B (zh) * 2014-12-15 2018-07-17 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体8B
CN104531731B (zh) * 2014-12-15 2018-06-26 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体7D
CN104531867B (zh) * 2014-12-25 2017-03-29 湖北省农业科学院畜牧兽医研究所 产气荚膜梭菌肠毒素阳性菌双重荧光定量pcr快速检测试剂盒
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
JP7121016B2 (ja) 2017-01-23 2022-08-17 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 抗原に対する防御免疫の誘導
WO2018159476A1 (ja) * 2017-02-28 2018-09-07 一般財団法人阪大微生物病研究会 多価ワクチン
CA3064461A1 (en) * 2017-05-31 2018-12-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Vaccine against necrotic enteritis in poultry
CA3064357A1 (en) 2017-06-09 2018-12-13 Hipra Scientific, S.L.U. Vaccine comprising clostridium toxoids
BR112020002374A2 (pt) 2017-08-04 2020-09-08 University Of Florida Research Foundation, Incorporated indução de imunidade protetora contra antígenos
CN107596361B (zh) * 2017-09-12 2020-08-14 浙江海隆生物科技有限公司 牛a型产气荚膜梭菌的亚单位疫苗及其制备方法和应用
CN107875377B (zh) * 2017-11-06 2020-01-03 山东农业大学 一种e型产气荚膜梭菌类毒素疫苗的制备方法
CN109954135B (zh) * 2017-12-25 2023-01-31 金宇保灵生物药品有限公司 牛a型产气荚膜梭菌灭活类毒素疫苗及其制备方法
US12144854B2 (en) * 2018-03-02 2024-11-19 One Health Ventures Ltd Epsilon toxin from clostridium perfringens as a vaccine
CN108578686B (zh) * 2018-04-23 2022-07-01 杨凌凯瑞生物科技有限公司 一种制备羊梭菌病基因工程亚单位疫苗的方法
CN109111509B (zh) * 2018-09-19 2021-08-13 天康制药(苏州)有限公司 腐败梭菌α毒素突变体、表达其的基因、制备方法和腐败梭菌疫苗
CN111500482B (zh) * 2019-01-31 2023-09-05 内蒙古金宇保灵生物技术研究院有限公司 一种羊a型产气荚膜梭菌菌株及其灭活疫苗和疫苗制备方法
CN109943507B (zh) * 2019-03-26 2021-08-17 中国兽医药品监察所 一种兽用a型产气荚膜梭菌类毒素的制备方法及其应用
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN115477699A (zh) * 2022-10-14 2022-12-16 华中农业大学 抗产气荚膜梭菌卵黄抗体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257230B1 (ru) * 1973-09-14 1976-11-19 Agronomique Inst Nat Rech
SU627610A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат землаково в.п. против клюстридиозов животных и птиц
ATE226635T1 (de) * 1992-05-20 2002-11-15 Secr Defence Clostridium perfringens impfstoffe
PT692974E (pt) * 1993-03-29 2003-09-30 Pfizer Vacinas clostridiais com multiplos componentes usando adjuvantes de saponina
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
WO2003099325A1 (en) * 2002-05-21 2003-12-04 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and user thereof
WO2005002509A2 (en) 2003-06-09 2005-01-13 Corixa Corporation Dna vectors
CA2535618A1 (en) 2003-08-14 2005-02-24 Merial Limited Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen
CA2583113C (en) * 2004-10-05 2015-11-10 Diversa Corporation Compositions comprising an antigen and a promiscuous t-cell epitope
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
US20100062025A1 (en) * 2006-11-20 2010-03-11 Intervet International B.V. Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOVLAND A et al. Maternal vaccination against subclinical necrotic enteritis in broilers, Avian Pathol, 2004 Feb, Vol.33(1), p.83-92. *

Also Published As

Publication number Publication date
BRPI0610843A2 (pt) 2010-07-27
EP1874344A1 (en) 2008-01-09
EP1874344B1 (en) 2016-06-08
US8980283B2 (en) 2015-03-17
TW200719910A (en) 2007-06-01
MA29406B1 (fr) 2008-04-01
NZ562637A (en) 2010-06-25
CR9443A (es) 2008-02-20
RU2007142337A (ru) 2009-05-27
AU2006236365A1 (en) 2006-10-26
US20150140033A1 (en) 2015-05-21
ES2583484T3 (es) 2016-09-21
MY149604A (en) 2013-09-13
MX2007013053A (es) 2008-01-14
ZA200709516B (en) 2008-11-26
DK1874344T3 (en) 2016-09-19
AR054251A1 (es) 2007-06-13
AU2006236365B2 (en) 2012-02-02
CA2606180C (en) 2016-09-13
SG186672A1 (en) 2013-01-30
KR20080005277A (ko) 2008-01-10
US20060233825A1 (en) 2006-10-19
PE20061398A1 (es) 2007-01-15
JP5243951B2 (ja) 2013-07-24
CN101198352A (zh) 2008-06-11
TNSN07387A1 (en) 2009-03-17
JP2012062330A (ja) 2012-03-29
UA98099C2 (ru) 2012-04-25
WO2006113772A1 (en) 2006-10-26
TWI311057B (en) 2009-06-21
JP2008536936A (ja) 2008-09-11
BRPI0610843B1 (pt) 2021-11-30
CA2606180A1 (en) 2006-10-26
IL186701A0 (en) 2008-02-09
US9662380B2 (en) 2017-05-30
CN101198352B (zh) 2011-07-27

Similar Documents

Publication Publication Date Title
RU2434638C2 (ru) Вакцина альфа токсоида с.perfringens
KR0162646B1 (ko) 보조제로서 토콜을 함유한 백신 및 그것의 제조방법
Petrovsky Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity
Azegami et al. Challenges in mucosal vaccines for the control of infectious diseases
Gasparini et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
RU2349342C2 (ru) Менингококковые вакцины для введения через слизистую оболочку
EA200900024A1 (ru) Противогриппозная вакцина
TW200722101A (en) Novel composition
AR072378A1 (es) Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos.
Song et al. An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
JP2009532353A5 (ru)
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
JPH0639386B2 (ja) アジュバント生ワクチンの製造方法
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
FI100946B (fi) Menetelmä adjuvanttia sisältävän antigeeniliuoksen valmistamiseksi
Ibarra‐Moreno et al. Coadministration of protoxin C ry1 A c from B acillus thuringiensis with metacestode extract confers protective immunity to murine cysticercosis
ATE310008T1 (de) Immunologische adjuvans verbindungen
Uggla et al. Immunizing effects in mice of two Toxoplasma gondii iscom preparations
RU2355423C1 (ru) Адъювант
HUP0104125A2 (hu) Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
WO2000037045B1 (en) Stabilized water-in-oil-in-water antigen delivery system
Isaka et al. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice
Morein Iscoms

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20150729

MM4A The patent is invalid due to non-payment of fees

Effective date: 20200418